Table 2. Univariate and multivariate analyses of NSCLC patients with PFS.

Variables	Univariate analysis			Multivariate analysis
	HR (95% CI)	P		HR (95% CI)*	P*
Gender
Male vs. female	0.71 (0.36–1.38)	0.306
Age
≤60 vs. >60	0.83 (0.39–1.80)	0.643
Smoking history
Yes vs. no	1.17 (0.59–2.31)	0.661
Stage
III vs. IV	0.73 (0.34–1.57)	0.416
Pathologic type
Adenocarcinoma
Squamous cell carcinoma	0.52 (0.26–1.06)	0.073		0.62 (0.27–1.43)	0.262
Main therapy (III&IV)
Targeted therapy
Non-targeted therapy	0.50 (0.21–1.17)	0.108		0.89 (0.33–2.39)	0.811
CTCs
≥7 vs. <7	3.25 (1.56–6.78)	0.002		2.89 (1.36–6.17)	0.006
CTC-WBC clusters
≥1 vs. <1	2.17 (1.08–4.36)	0.030		2.18 (1.07–4.43)	0.031

*, adjusted for pathologic type, main therapy, number of CTCs, and CTC-WBC clusters. HR, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; CTC, circulating tumor cell; CTC-WBC cluster, circulating tumor-cell-associated white blood cell cluster.